Evaluation of the Neurocognitive and Emotional Functions in Addicts Treated with Methadone and Buprenorphine

Madanifard, Mehdi; Mazaheri, Mehrdad; Bigdeli, Imanolah

doi:10.29252/shefa.6.3.25

[Home ] [Archive]

[ فارسی ]

The Neuroscience Journal of Shefaye Khatam

Main Menu

Home

Journal Information

Articles Archive

Guide for Authors

For Reviewers

Ethical Statements

Registration

Site Facilities

Contact us

Search in website

Receive site information

Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Volume 6, Issue 3 (Summer - 2018)

Shefaye Khatam 2018, 6(3): 25-34

Back to browse issues page

Evaluation of the Neurocognitive and Emotional Functions in Addicts Treated with Methadone and Buprenorphine

Mehdi Madanifard ^*

, Mehrdad Mazaheri

, Imanolah Bigdeli

Department of Psychology, Faculty of Education and Psychology, Ferdowsi University of Mashhad, Mashhad, Iran , psy.madani@yahoo.com

Abstract: (5912 Views)

Introduction: Cognitive and emotional factors play a crucial role in addiction treatment. The aims of this study was to evaluate cognitive emotional regulation and neurocognitive functioning in addicts treated with methadone and buprenorphine. Materials and Methods: The current study was a cross-sectional and causal-comparative study. Statistical population of this research include all men of maintenance substance treatment. The population evaluated in this study consisted of 50 patients treated with methadone and 50 patients treated with buprenorphine in Mashhad Addiction Recovery Center during 2016. The Barkley deficits in Executive Functioning Scale (BDEFS) and Garnofsky's Emotion Regulation Scale were evaluated for all individuals. Data analysis was performed using descriptive indicators and independent t-test. Results: The results showed that the mean score in the cognitive emotion regulation scale of the buprenorphine-treated group were higher than the methadone-treated group. In contrast, the methadone-treated group received a significant higher score in BDEFS test compared to the buprenorphine group. Conclusion: Although both methadone and buprenorphine lead to a reduction in neurocognitive functioning and emotion regulation, buprenorphine seems to be a better drug to preserve cognitive function during treatment of addiction.

Keywords: Methadone, Buprenorphine, Emotions

Full-Text [PDF 748 kb] (3644 Downloads)

Type of Study: Research --- Open Access, CC-BY-NC | Subject: Cognitive Neuroscience

References

1. Dallas TX, David W, Julie K. Staley behavioral neuroscience of drug addiction. Biosocieties. 2010; 39: 22-6.

2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5Th ed. Washington, DC: APA. 2013.

3. Mokri A. Brief overview of the status of drug abuse in Iran. Archives of Iranian Medicine. 2002; 5: 184-90.

4. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, Braff DL. Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. Neuropsychopharmacology. 2002; 26(1): 53-6. [DOI:10.1016/S0893-133X(01)00334-7]

5. Lyvers G, Leggio L, Abenavoli L, Gasbarrini G. Neurobiochemical and clinical aspects of craving in alcohol addiction: a review. Addict Behav. 2005; 30(6): 1209-24. [DOI:10.1016/j.addbeh.2004.12.011]

6. Czuchry M, Dansereau DF. Cognitive skills training: impact on drug abuse counseling and readiness for treatment. Am J Drug Alcohol Abuse. 2003; 29(1): 1-18. [DOI:10.1081/ADA-120018837]

7. Witkiewitz K, Marlatt A, Walker D. Ming – fullness- based relapse prevention for alcohol and substance use disorders. J Cogn Psychother. 2005; 19: 221-2. [DOI:10.1891/jcop.2005.19.3.211]

8. McLellan AG, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA. 1993; 269(15): 1953-9. [DOI:10.1001/jama.1993.03500150065028]

9. Layson-Wolf C, Goode JV, Small RE. Clinical use of methadone. J Pain Palliat Care Pharmacother. 2002; 16(1): 29-59. [DOI:10.1080/J354v16n01_04]

10. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007; 11(9):1-171. [DOI:10.3310/hta11090]

11. Huizinga M, Dolan C, Van Der Molen M. Age-related change in executive function: developmental trends and a latent variable analysis. Neuropsychol. 2006; 44(11): 2017-36. [DOI:10.1016/j.neuropsychologia.2006.01.010]

12. Soyka M, Horak M, Dittert S, Kagerer S. Less driving impairment on buprenorphine than methadone in drug-dependent patients? J Neuropsychiatry Clin Neurosci. 2001; 13(4): 527-8. [DOI:10.1176/jnp.13.4.527]

13. Soyka M, Hock B, Kagerer S, Lehnert R, Limmer C, Kuefner H. Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine- maintained than in methadone-maintained patients. results of a randomized clinical trial. J Clin Psychopharmacol. 2005; 25(5): 490-3. [DOI:10.1097/01.jcp.0000178417.60426.60]

14. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, et al. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend. 2004; 75(1): 37-45. [DOI:10.1016/j.drugalcdep.2003.11.017]

15. Barkley RA. Deficits in executive functioning scale (BDEFS). New York: Guilford Press; 2011.

16. Lyvers G, Leggio L, Abenavoli L, Gasbarrini G. Neurobiochemical and clinical aspects of craving in alcohol addiction: a review. Addictive Behaviors. 2005; 30(6): 1209-24. [DOI:10.1016/j.addbeh.2004.12.011]

17. Lezak MD. Neuropsychological assessment. 3rd ed. New York: Oxford University Press. 1995.

18. Bechara A, Dolan S, Denburg N, Hindes A, Anderson SW. Nathan PE. Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol a stimulant abuser. Neuropsychologia. 2001; 39(4): 376-89. [DOI:10.1016/S0028-3932(00)00136-6]

19. Darke S, Sims J, Mcdonald S, Wicks W. Cognitive impairment among methadone maintenance patients. Addiction. 2000; 95(5): 687-95. [DOI:10.1046/j.1360-0443.2000.9556874.x]

20. Giacomuzzi SM, Thill C, Riemer Y, Garber K, Ertl M. Buprenorphine-and methadone maintenance treatment: influence on aspects of cognitive and memory performance. Open Addict J. 2008; 1: 5-6. [DOI:10.2174/1874941000801010005]

21. Taube-Schiff M, Van Exan J, Tanaka R, Wnuk S, Hawa R, Sockalingam S. "Attachment style and emotional eating in bariatric surgery candidates: the mediating role of difficulties in emotion regulation". Eat Behav. 2015; 18: 36-40. [DOI:10.1016/j.eatbeh.2015.03.011]

22. Aldao A, Nolen-Hoeksema S, Schweizer S. Emotion-regulation strategies across psychopathology: a meta-analytic review. Clin Psychol Rev. 2010; 30(2): 217-37. [DOI:10.1016/j.cpr.2009.11.004]

23. Garnefski N, Teerds J, Kraaij V, Legerstee J, Van den Kommer T. Cognitive emotion regulation strategies and depressive symptoms: differences between males and females. Pers Individ Dif. 2004; 36(2): 267-76. [DOI:10.1016/S0191-8869(03)00083-7]

24. Barlow DH, Allen LB, Choate ML. Toward a unified treatment for emotional disorders. Behav Ther. 2004; 35(2): 205-230. [DOI:10.1016/S0005-7894(04)80036-4]

25. Savvas S, Somogyi A, White J. The effect of methadone on emotional reactivity. Addiction. 2012;107(2): 388-92. [DOI:10.1111/j.1360-0443.2011.03634.x]

26. Rolley E. Pharm D. Mary C. Eric S. Shahron W. Maxiline L. et al. A comparison of l evomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000; 324(2): 1290-4.

27. Yusefi F. The relationship of cognitive emotion regulation strategies with depression and anexiety in the middle students. Except Child. 2007; 4: 871-92.

28. Mashhadi A, Mirdoraghi F, Hosainzadeh-Maleki Z, Hasani J, Hamzeloo M. Factor structore, reliability and validity of persian version of barkeley deficits in executive functioning scale(BDEFS)- adult version. J Clin Psychol. 2015; 7(1): 51-62.

29. Rapeli P, Carola Fabritius C, Kalska H, Alho H. Memory function in opioid dependent patients treated with methadone or buprenorphine along with benzodiazepine: longitudinal change in comparison to healthy individuals. Subst Abuse Treat Prev Policy. 2009; 4: 6. doi:10.1186/1747-597X-4-6. [DOI:10.1186/1747-597X-4-6]

30. Rapeli P, Carola Fabritius C, Kalska H, Alho H. Cognitive functioning in opioid dependentpatients treated with buprenorphine, methadone,and other psychoactive medications: stability and correlates. BMC Clin Pharmacol. 2011; 11: 13. doi.org/10.1186/1472-6904-11-13. [DOI:10.1186/1472-6904-11-13]

31. Lundqvist T. Cognitive consequences of connobese use in comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav. 2005; 81(2): 319-30. [DOI:10.1016/j.pbb.2005.02.017]

32. Von Geusau NA, Stalenhoef P, Huizinga M, Snel J, Ridderinkhof KR. Impaired executive function in male MDMA (''ecstasy'') users. Psychopharmacology (Berl). 2004; 175(3): 331-441. [DOI:10.1007/s00213-004-1832-8]

33. Hampshire A, Owen AM. Fractionating attentional control using eventrelated fmri. Cereb Cortex. 2006; 16(12): 1679-89. [DOI:10.1093/cercor/bhj116]

34. Rapeli P, Fabritius C, Alho H, Salaspuro M, Wahlbeck K, Kalska H. Methadone vs buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performancerelative to healthy controls. BMC Clin Pharmacol. 2007; 7: 5. doi.org/10.1186/1472-6904-7-5. [DOI:10.1186/1472-6904-7-5]

35. Trindad DR, Unger Jb, Chou CO, Johnson A. The protective association of emotional intellegence with psychosocial smoking risking factors factor adolescent. personality and individual differences. Pers Individ Dif. 2004; 36(4): 945-54. [DOI:10.1016/S0191-8869(03)00163-6]

36. Trindad DR, Johnson CA. The association between emotion intelligence and early adolescent tobaco and alcohol use. Pers Individ Dif. 2002; 3(21): 95-105. [DOI:10.1016/S0191-8869(01)00008-3]

37. Wills TA, Vaccaro D, Mcnamara G. Novehty seeking, risk taking and related constructs as predictors of adolescent substance use: an application of cloninger s theory. J Subst Abuse. 1994; 6(1): 1-20 [DOI:10.1016/S0899-3289(94)90039-6]

38. Ipser JC1, Terburg D, Syal S, Phillips N, Solms M, Panksepp J, et al. Reduced fear-recognition sensitivity following acute buprenorphine administration in healthy volunteers. Psychoneuroendocrinology. 2013; 38(1): 166-70. [DOI:10.1016/j.psyneuen.2012.05.002]

39. Bershad AK, Seiden JA, de Wit H. Effects of buprenorphine on responses to social stimuli in healthy adults. Psychoneuroendocrinology. 2016; 63:43-9. [DOI:10.1016/j.psyneuen.2015.09.011]

40. Narimani M, Abasi M, Abolghasemi A, Ahadi B. Comparison of the effectiveness of acceptance / commitment with emotion regulation training on adjustment of students with dyscalculia. Middle Eastern Journal of Disability Studies. 2013; 4(2): 174-76.

‎ 10.29252/shefa.6.3.25

Mendeley

Zotero

RefWorks

Madanifard M, Mazaheri M, Bigdeli I. Evaluation of the Neurocognitive and Emotional Functions in Addicts Treated with Methadone and Buprenorphine. Shefaye Khatam 2018; 6 (3) :25-34
URL: http://shefayekhatam.ir/article-1-1743-en.html

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Volume 6, Issue 3 (Summer - 2018)

Back to browse issues page

Persian site map - English site map - Created in 0.05 seconds with 45 queries by YEKTAWEB 4645